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Editorial
The International Society of Gynecological Pathologists
(ISGyP) Endometrial Carcinoma Project
W. Glenn McCluggage, F.R.C.Path., Anais Malpica, M.D., Xavier Matias-Guiu, M.D.,
Esther Oliva, M.D., and Vinita Parkash, M.D.
Endometrial carcinoma is the commonest gyneco-
logical malignancy in developed countries, and the
various aspects of the pathology report are critical for
patient management. There are many areas of
controversy with regard to the handling of resection
specimens and the pathologic reporting of endome-
trial carcinomas. These controversies include those
related to sampling, diagnosis, reporting of parame-
ters important for staging, and the undertaking of
ancillary studies. These controversies stimulated the
International Society of Gynecological Pathologists
(ISGyP) endometrial carcinoma project. The project
was devised at the ISGyP Board of Directors meeting
in March 2015 under the Presidency of Richard
Zaino. An organizing committee was selected from
the members of the Board of Directors and the
education committee of the ISGyP. The organizing
committee (comprising the 5 authors of this editorial),
as a first step, devised a comprehensive survey, which
was emailed to all members of the ISGyP; the survey
covered all aspects of endometrial cancer reporting,
including specimen dissection and sampling, diagno-
sis, staging, prognostic factors, and ancillary studies.
Following the survey, the members of the organiz-
ing committee devised a series of key questions
chosen to encompass the various areas of controversy.
These questions were divided into three major groups
(a-Diagnosis; b-Processing, Sampling, Staging, and
Prognosis; c-Special Techniques/Ancillary Studies).
For each group, 5 “lead” pathologists were selected
by the organizing committee, and ∼15 other pathol-
ogists were selected for each group to work on the
various questions. Usually, 3 pathologists worked on
each question, their task being to critically review the
literature and to come up with recommendations,
which were to be “evidence-based” if possible,
although it was recognized that this was not feasible
when the levels of evidence were weak. A commentary
with selected important references was produced for
each question. Many of the recommendations were
presented and discussed at an ISGyP-sponsored
symposium in Seattle before the United States and
Canadian Academy of Pathology meeting in March
2016; some of the recommendations and commen-
taries were amended following these discussions.
The recommendations and associated commentaries
are presented in the various articles in this issue of
International Journal of Gynecological Pathology. The
first article details the results of the survey undertaken
before the start of the project. This provides important
background information with regard to current practices
worldwide. The second article covers the important issue
of sampling of resection specimens of endometrial
carcinomas. The following 3 articles deal with various
aspects related to the diagnosis of the different
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morphologic subtypes of endometrial carcinoma, the
sometimes problematic distinction between an endome-
trial and a cervical carcinoma, and the issue of
synchronous endometrial and adnexal carcinomas. An
important recommendation is that endometrioid carci-
nomas be graded using a binary International Feder-
ation of Gynecology and Obstetrics grading system
rather than the current 3-tier International Federation of
Gynecology and Obstetrics grading system. Advice is
provided as to how to incorporate the 4 genomic
subcategories of endometrial carcinoma, as identified
through The Cancer Genome Atlas Study, into clinical
practice. The next article deals with parameters that are
important in the staging and prognosis of endometrial
carcinomas and provides recommendations with regard
to the many controversial issues.
The final 2 articles cover ancillary studies with a
recommendation that all endometrial carcinomas be
tested for mismatch repair protein abnormalities and
possible Lynch syndrome using immunohistochemistry
for mismatch repair proteins as the initial modality.
Given the wide usage of p53 immunohistochemistry in
the diagnosis of endometrial carcinomas and the well-
known problems in the interpretation of p53 staining, a
separate article is devoted to p53 immunohistochem-
istry; this provides important recommendations with
regard to the methods of p53 immunohistochemical
staining and interpretation.
It has been a great pleasure for us to organize this
project and to help in coordinating and writing the
various articles. We are thankful to all the patholo-
gists who participated in the project and the authors
of the various articles. We hope the articles will serve
as important reference material for pathologists
currently and in the future and aid in the stand-
ardization of sampling, diagnosis, and reporting of
endometrial carcinomas, which will benefit patients
with this disease. We recognize that this is a rapidly
evolving field, and regular updating of these recom-
mendations will be necessary in the future.
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